AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
AbbVie Reports Third-Quarter 2023 Financial Results
October 27, 2023 7:38 AM EDTReports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones Expense
Delivers Third-Quarter Net Revenues of $13.927 Billion, a Decrease of 6.0 Percent on a Reported Basis and 5.8 Percent on an Operational Basis
Third-Quarter Global Net Revenues from the Immunology Portfolio Were $6.783 Billion, a Decrease of 11.3 Percent; Global Humira Net Revenues Were $3.547... More
